SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 29, 2017
|SECOND SIGHT MEDICAL PRODUCTS, INC.|
|(Exact Name of Registrant as Specified in Its Charter)|
|(State or Other Jurisdiction of Incorporation)|
|(Commission File Number)||(IRS Employer Identification No.)|
12744 San Fernando Road, Suite
|(Address of Principal Executive Offices)|
|(Registrant’s Telephone Number, Including Area Code)|
|(Former Name or Former Address, if Changed Since Last Report)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
- 1 -
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Change in Duties of Dr. Gregoire Cosendai.
On September 29, 2017, the Board of Directors of Second Sight Medical Products, Inc. (the “Company”) appointed Gregoire Cosendai to be Vice President Clinical Affairs. Dr. Cosendai will direct or oversee clinical activities relating to Orion I and all other clinical activities of the Company. He will continue to report to the Company’s CEO, Will McGuire. Dr. Cosendai was formerly Vice President of European Operations.
ITEM 8.01 Other Events
Effective October 1, 2017, the Company retained Frank Vandeputte, through his personal service company, to act as Vice President and General Manager, EMEA and Asia Pacific. Mr. Vandeputte is principally tasked with overseeing sales and marketing outside of North America, and will report to the Company’s CEO, Will McGuire. Mr. Vandeputte has extensive international sales and marketing experience in the medical device industry, including with multiple start-up companies.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 4, 2017
SECOND SIGHT MEDICAL PRODUCTS, INC.
|/s/ Thomas B. Miller|
By: Thomas B. Miller
Chief Financial Officer
- 2 -